

CORPORATE FACT SHEET

AUGUST 2009



Selected Data

Stock listing:	NASDAQ: ABII
Recent price: (August 19, 2009)	\$28.27
52 wk price range:	\$25.82 - \$74.99
Market cap: (August 19, 2009)	\$1.2 billion
Average volume:	35,034 shares
Shares outstanding:	40 million
Float:	7 million
2008 Revenues:	\$345 million
Cash/cash equivalents: (June 30, 2009)	\$258 million


Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies to offer patients safer and more effective treatments for cancer and other critical illnesses.

The company's portfolio includes the world's first and only protein-bound chemotherapeutic compound, ABRAXANE[®] for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound), which is based on the company's proprietary tumor targeting technology known as the *nab*[™] platform. The first FDA approved product to use this *nab* platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer.*

Abraxane[®]
for Injectable Suspension
(paclitaxel protein-bound particles for injectable suspension)
(albumin-bound)



ABRAXANE[®] is Approved for Marketing in 38 Countries



ABRAXANE[®] is a solvent-free chemotherapy treatment option for metastatic breast cancer which was developed using Abraxis BioScience's proprietary nab[®] technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin, a naturally-occurring human protein. By wrapping the albumin around the active drug, ABRAXANE can be administered to patients at higher doses, delivering higher concentrations of paclitaxel to the tumor site than solvent-based paclitaxel. Nab-paclitaxel is currently in various stages of investigation for the treatment of the following cancers: expanded applications for metastatic breast, non-small cell lung, malignant melanoma, pancreatic and gastric.

*ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Please see the important safety information, including the Boxed Warning, below. Please see the enclosed full US prescribing information for ABRAXANE, including the Boxed Warning, or visit www.abraxane.com.

ABRAXANE is approved for marketing in the United States, Europe, Canada, India, UAE, South Korea, China and Australia. ABRAXANE is marketed in the U.S., Canada and Europe by Abraxis BioScience. The company has partnerships in India with Biocon Limited; in Korea with Green Cross Corporation; and in Japan with Taiho Pharmaceutical Co., Ltd.

ABRAXANE REVENUE (Year ended December 31) (\$ millions)



Company Highlights


- Revenue growth and strong cash flow generated from successful commercialization of first product derived from proprietary *nab* technology platform
- Opportunity for continued growth through worldwide commercialization of ABRAXANE[®]; Growing market share in North America; recently launched in the U.K. and Germany; partnerships in India, Australia, Korea and Japan
- Fully integrated biotechnology company with expertise in drug discovery, drug delivery, clinical development, regulatory affairs, nanoparticle manufacturing, and sales and marketing; Global management team in place to establish comprehensive commercialization infrastructure
- Diverse and late-stage product pipeline, including ABRAXANE for multiple oncology indications, addressing global market exceeding \$5 billion; Significant opportunities to use *nab* platform to deliver new and existing therapeutic compounds
- Broadening drug discovery prospects through multiple academic and global strategic collaborations
- Expanding research into predictive, personalized evidence-based medicine
- Strong cash position of more than \$258 million at June 30, 2009 to capitalize on multiple growth opportunities

Investor Contact:

Mailli Bergman
Director, Investor Relations
(310) 405-7522
investorrelations@abraxisbio.com

Abraxis BioScience Clinical Program

In addition to commercializing ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) (ABI-007) globally, Abraxis has an extensive clinical development plan underway. To advance the clinical knowledge of ABRAXANE and its commercial potential, as of the first quarter of 2009, the clinical program consisted of three Phase 3 clinical trials, 15 Phase 2 studies, 11 Phase 1/2 studies and over 60 investigator-initiated Phase 1 and 2 clinical trials and preclinical studies.



Please see the important safety information, including the Boxed Warning, below. Please see the enclosed full US prescribing information for ABRAXANE, including the Boxed Warning, or visit www.abraxane.com.

Key Collaborations

Biocon Limited

Rights to commercialize ABRAXANE in India, Pakistan, Bangladesh, and Sri Lanka, and certain other South Asian and Persian Gulf countries; Abraxis gains rights for Biocon's biosimilar G-CSF in North America and the European Union

Cenomед Biosciences, LLC

Designed to advance the research and development of novel drugs that interact with the central nervous system with a focus on psychiatric and neurological diseases

Green Cross Corporation

Rights to commercialize ABRAXANE in Korea; Abraxis gains rights to commercialize the following Green Cross biosimilars in North America: erythropoetin, pegylated G-CSF, Interferon-Alpha, recombinant Factor VIII, and Enbrel[®] (etanercept)

Taiho Pharmaceutical Co., Ltd.

Rights to commercialize ABRAXANE in Japan

Buck Institute for Age Research

Worldwide intellectual property rights for technologies designed to generate novel therapeutics and identify drug discovery targets

California NanoSystems Institute at UCLA (CNSI)

Collaboration agreement on early research in nanobiotechnology for the advancement of new technologies in medicine

Saint John's Health Center

Initiative to blend translational research, bioinformatics and clinical patient care to advance treatments for cancer, neuroscience, heart disease and orthopedics

Translational Genomics Research Institute

Advance life sciences research in Arizona; launch a National Personalized Health Network to increase the conduct of evidence-based personalized medicine clinical trials

University of Southern California

Exclusive worldwide rights for portfolio of diagnostic protein biomarkers for colorectal cancers (CRCs)

ProMetic Life Sciences Inc.

Global program to develop and commercialize novel biopharmaceuticals using ProMetic's proprietary protein technologies



Corporate Headquarters
11755 Wilshire Blvd., 20th Fl.
Los Angeles, CA 90025
Tel: (310) 883-1300
www.abraxisbio.com

Manufacturing Locations
Phoenix, Arizona
Melrose Park, Illinois
Barceloneta, Puerto Rico

Other Locations
Marina Del Rey, CA
Auburn, CA
Bridgewater, NJ
Durham, NC

Mjississauga, On Canada
London, UK
Paris, France
Beijing, China

Abraxane[®] for Injectable Suspension

(paclitaxel protein-bound particles for injectable suspension)
(albumin-bound)

Important Safety Information & Boxed Warning

You should receive ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) under the care of a doctor who is trained to use cancer drugs. Because you may have side effects from your treatment, you should get this medicine in a clinic or hospital with doctors, nurses, and pharmacists who are trained to give cancer drugs.

ABRAXANE therapy should not be given to patients with metastatic breast cancer who have low blood counts. Low blood counts, especially low white blood cell counts, may make you more likely to get an infection. In order to check for low blood counts your doctor may need to take some blood to test your blood counts.

Note: Abraxane is paclitaxel made with the human blood protein albumin. This makes it behave differently in the body than regular paclitaxel. DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL DRUGS.

Important Safety Information

One of the more important side effects associated with chemotherapy is neutropenia, which is a decrease in the number of infection-fighting white blood cells (neutrophils). Normal levels range from approximately 1,500 cells/mm³ to 1,800 cells/mm³ (but vary according to several factors, such as age and race). If levels fall below 500 cells/mm³, your risk of developing an infection increases and treatment may be interrupted. To avoid the risk of serious infection and fever, your doctor will monitor your absolute neutrophil count (ANC) during therapy.

Women should avoid becoming pregnant while being treated with ABRAXANE. Tell your doctor if you are pregnant, if you become pregnant, or you plan to become pregnant while taking ABRAXANE. Discuss with your doctor how ABRAXANE may affect fertility. Nursing a baby while taking ABRAXANE is not recommended because the drug may be present in breast milk.

The most important adverse events included lower white and red blood cell counts, infections, tingling and numbness, nausea, vomiting, diarrhea, muscle and joint aches, and mouth sores. Other adverse reactions included weakness, visual disturbances, fluid retention, hair loss, and liver and kidney dysfunction. Low platelet counts, allergic reactions (which in rare cases were severe), cardiovascular reactions, and injection site reactions were uncommon.

Sensory neuropathy (numbness, tingling, or burning in the hands and feet) can occur with ABRAXANE and other paclitaxel medications. Severe sensory neuropathy can improve with proper management, as prescribed by your doctor. You should tell your nurse or doctor if you experience numbness, tingling, or burning in your hands or feet while taking ABRAXANE.

Please talk to your doctor or nurse if you have questions regarding the potential side effects of ABRAXANE therapy. You may want to review the Product Information, including Warnings, Precautions, and Contraindications.

1. ABRAXANE [prescribing information]. Los Angeles, Calif: Abraxis Oncology, a Division of Abraxis BioScience, Inc; August 2007.

Forward-Looking Statements

Certain statements in this fact sheet may be deemed to be forward-looking statements and are subject to the "safe-harbor" provisions contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements may include, but are not limited to, the company's discussion of its market opportunities and growth strategies. Many important factors may cause the company's actual results to differ materially from those discussed, including increased competition, integration risks associated with acquisitions, general economic and market conditions and the other risks and uncertainties described in the company's filings made from time to time with the Securities and Exchange Commission.

Please see the enclosed full US prescribing information for ABRAXANE, including the Boxed Warning, or visit www.abraxane.com.



11755 Wilshire Blvd., 20th Floor
Los Angeles, CA 90025
Tel: (310) 883-1300
www.abraxisbio.com

August 2009